Cerdelga Evrópusambandið - rúmenska - EMA (European Medicines Agency)

cerdelga

sanofi b.v. - eliglustat - boala gaucher - alte medicamente pentru tractul digestiv și metabolism, - cerdelga este indicat pentru tratamentul pe termen lung a pacienţilor adulţi cu boala gaucher de tip 1 (extensiile gd1), care sunt metabolisers de slaba cyp2d6 (pms), intermediar metabolisers (ims) sau metabolisers extinsă (ems).

Imbruvica Evrópusambandið - rúmenska - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.